Guardant Health, Inc. (GH)

17,35 +0,19 (+1,11%) Alla chiusura: 04:00PM EDT

Guardant Health, Inc.

3100 Hanover Street
Palo Alto, CA 94304
United States
855 698 8887
https://guardanthealth.com

Settore/i: Healthcare
Settore: Diagnostics & Research
Impiegati a tempo pieno: 1.768

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Helmy Eltoukhy Ph.D.	Co-Founder, Co-CEO & Chairman	11,59k	N/D	1980
Dr. AmirAli Talasaz Ph.D.	Co-CEO & Director	26,41k	N/D	1980
Mr. Michael Bell	Chief Financial Officer	819,27k	N/D	1969
Ms. Darya Chudova	Chief Technology Officer	715,66k	N/D	1974
Dr. Craig Eagle M.D.	Chief Medical Officer	844,86k	N/D	1967
Mr. Christopher Freeman	Chief Commercial Officer	826,27k	N/D	1974
Mr. Kumud Kalia	Chief Information Officer	N/D	N/D	1966
Mr. John G. Saia	Chief Legal Officer & Corporate Secretary	627,18k	N/D	1973
Ms. Jennifer Higgins	Senior Vice President of Public Affairs	N/D	N/D	N/D
Ms. Terilyn Juarez Monroe	Chief People Officer	N/D	N/D	1967

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Governance aziendale

L'ISS Governance QualityScore di Guardant Health, Inc. al 1 aprile 2024 è 7. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 7; diritti degli azionisti: 8; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.